Stockscreener 앱 받기
197.74
2.67%
-5.42
시간 외 거래:
199.57
1.83
+0.93%
전일 마감가:
$203.16
열려 있는:
$203.7
하루 거래량:
840.96K
Relative Volume:
0.68
시가총액:
$29.19B
수익:
$9.60B
순이익/손실:
$1.37B
주가수익비율:
21.22
EPS:
9.3182
순현금흐름:
$2.32B
1주 성능:
+0.25%
1개월 성능:
-0.99%
6개월 성능:
+13.77%
1년 성능:
+54.67%
1일 변동 폭
$197.40
$204.31
1주일 범위
$194.67
$215.79
52주 변동 폭
$124.56
$219.72
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
197.74 | 29.99B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,163.01 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.63 | 603.27B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
253.30 | 452.48B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.47 | 311.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.08 | 292.46B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 업그레이드 | UBS | Neutral → Buy |
| 2026-04-20 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2025-11-06 | 업그레이드 | Stifel | Hold → Buy |
| 2025-09-25 | 개시 | Jefferies | Buy |
| 2025-07-21 | 재개 | Truist | Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen stock trades steady as revenue growth and Alzheimer’s portfolio shape outlook - Ad-hoc-news.de
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Former Biogen Executive to Lead Research at Formation Bio - Bloomberg.com
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
BofA cuts Biogen stock price target on higher expectations bar - Investing.com
BofA cuts Biogen stock price target on higher expectations bar By Investing.com - Investing.com Canada
Biogen stock steadies as Alzheimer’s launch and pipeline guide long-term growth - Ad-hoc-news.de
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There? - simplywall.st
FDA 'Gets to Pick the Jury': Steve Uden on Biogen's Tau Gamble and a UK Political Reset - finance.biggo.com
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast - biocentury.com
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Brings On Spur Therapeutics CEO As Legal Chief - Law360
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating - marketscreener.com
Biogen stock edges higher as Alzheimer’s and neuromuscular pipeline shapes outlook - ad-hoc-news.de
Biogen stock trades steady as Alzheimer’s revenue and pipeline shape valuation - ad-hoc-news.de
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more - Endpoints News
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer - Bloomberg Law News
Biogen moves forward with Alzheimer's drug candidate following phase 2 study - medwatch.com
Tens of Thousands With Ataxias Can Access Virtual Care - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - The National Law Review
Rx Rundown: Biogen, Neko Health, Roche and more - Medical Marketing and Media
Is Biogen (BIIB) a Buy, Hold, or Sell Right Now - Kavout | AI
Biogen shares slide as diranersen data raise dosing question - The Pharma Letter
Roche/ Biogen kidney drug granted FDA priority review for label expansion - Seeking Alpha
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data - Yahoo Finance
Biogen names Michael Parini as chief legal officer - Investing.com
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Biogen names Michael Parini as chief legal officer By Investing.com - Investing.com Canada
Biogen Appoints Michael J. Parini as Chief Legal Officer - Biogen
Biogen's incoming legal chief has 20 years in biotech leadership - Stock Titan
Form S-1 Biogen Inc For: 15 July By Investing.com - Investing.com Nigeria
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data - Clinical Trials Arena
Tau In The Clinic, Again - Seeking Alpha
Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s DataHas The Bull Case Changed? - simplywall.st
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3 - NeurologyLive
Biogen stock holds steady as Alzheimer portfolio and pipeline shape the long-term story - Ad-hoc-news.de
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact - Yahoo Finance
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026Slideshow - Seeking Alpha
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors - GuruFocus
Biogen Inc.'s Stock Price Plummets to $191.95, Recording a Sharp 8.17% DropThe Latest Market Update - Smartkarma
Biogen (BIIB) Alzheimer’s Association International Conference (AAIC Meeting) 2026 summary - Quartr
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
0.05%
자본화:
|
볼륨(24시간):